TNM stage (sixth edition) | n | Pretreatment TLG | In-treatment TLG | ΔTLG (%) |
IIIA (n = 17) | ||||
T0N2 | 1 (4) | 83.60 | 26.93 | −67.79 |
T1N2 | 3 (11) | 27.35 | 15.34 | + 43.91 |
127.97 | 108.18 | −15.46 | ||
6.33 | 3.27 | −48.31 | ||
T2N2 | 8 (29) | 156.81 | 59.93 | −61.78 |
323.93 | 278.08 | −14.16 | ||
199.1 | 48.63 | −75.57 | ||
31.83 | 30.05 | −5.59 | ||
60.21 | 76.13 | +26.45 | ||
92.89 | 51.88 | −44.15 | ||
72.18 | 45.47 | −37.00 | ||
243.41 | 92.01 | −62.20 | ||
T3N2 | 5 (18) | 188.80 | 145.7 | −22.83 |
339.14 | 68.61 | −79.77 | ||
95.80 | 64.47 | −32.70 | ||
233.48 | 108.07 | −53.71 | ||
717.87 | 624.52 | −13.00 | ||
IIIB (n = 11) | ||||
T1N3 | 3 (11) | 263.68 | 398.50 | +51.13 |
49.79 | 20.44 | −58.94 | ||
163.20 | 74.16 | −54.56 | ||
T2N3 | 1 (4) | 224.42 | 84.67 | −62.27 |
T4N0 | 3 (11) | 77.19 | 36.98 | −52.10 |
199.84 | 26.00 | −86.99 | ||
676.20 | 416.06 | −38.47 | ||
T4N2 | 2 (7) | 489.18 | 174.15 | −64.40 |
1319.04 | 1042.25 | −20.98 | ||
T4N3 | 2 (7) | 339.64 | 177.56 | −47.72 |
210.71 | 152.9 | −27.43 |
Data in parentheses are percentages.